A suite of recent studies spanning oncology reveal novel biomarkers, immunotherapeutic targets, and precision medicine tools. Highlights include the identification of Ephrin B3 in cutaneous squamous cell carcinoma, enhancement of breast cancer detection via dual-targeting IHC, and new molecular markers for lung cancer cardiac cachexia. Advances in spatial and single-cell omics deepen understanding of tumor microenvironments, while innovative antibody-drug conjugates and fusion therapies progress in clinical development, promising refined therapeutic strategies.